
Polycythemia From Testosterone Therapy: To Treat or Not?
Severe, chronic polycythemia secondary to increased blood viscosity can raise pulmonary arterial pressure and cause increased pulmonary resistance with potential hypoxia, resulting in cor …
Polycythemia and Erythropoietin in a Patient With Chronic …
In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms …
Polycythemia and Erythropoietin in a Patient With Chronic
Hydronephrotic kidney disease can sometimes result in erythropoietin-associated secondary polycythemia, even in non-functioning kidneys. Here, Stark et al. present such a case in a 16 …
ACE inhibitors against altitude polycythemia - Medscape
Both forms of the disease are classified as "secondary" polycythemia, being secondary to increased levels of erythropoietin, a hormone produced by the kidney that regulates red blood …
Polycythemia and Erythropoietin in a Patient With Chronic …
Conclusion In rare cases, hydronephrotic kidney disease can be the cause of erythropoietin-associated secondary polycythemia, even in nonfunctioning kidneys.
Rusfertide: First Self-Injected Drug to Cut Phlebotomy
Rusfertide, an investigational, first-in-class, self-injected peptide targeting the hepcidin pathway, shows efficacy in significantly reducing the need for phlebotomy in patients with polycythemia ...
High in the Andes, a Possible Clue Into Blood Cancer
Armed with new findings, hematology researchers hope the unique genetic traits of Aymarans will offer new insight into myeloproliferative neoplasms such as polycythemia vera (PV) and …
Can We Prevent Myelofibrosis? The New Interferon Era
Join Drs Tania Jain and Brandi Reeves as they discuss primary myelofibrosis and post-ET (essential thrombocythemia) and post-PV (polycythemia vera) myelofibrosis.
Lower HCT Prevents CV Events in Polycythemia Vera
Polycythemia vera is a rare condition that is characterized as a panhyperplastic, malignant, and neoplastic marrow disorder.
JAK Inhibitors: Too Many Choices or Not Enough?
If you look at all the data, there are a couple of things I'll point out. One is the event-free survival improvement that was seen in the PROUD-PV and CONTINUATION-PV [polycythemia vera] …